Design and Development of a Novel Series of Orally-Active, Selective PI3K-p110ß/δ Inhibitors for the Treatment of Solid and Hematological Cancers

Design and Development of a Novel Series of Orally-Active, Selective PI3K-p110ß/δ Inhibitors for the Treatment of Solid and Hematological Cancers.
Bone E.A., Cecil A.R.L., Colman L., Finan P., Finnemore D., Gatland A., Haque K., Lensun L., Rogers H., Silva F.A., Whale A., Shuttleworth S.J.
Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3639.